Compare OCGN & NBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCGN | NBY |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 387.3M | 398.2M |
| IPO Year | N/A | 2007 |
| Metric | OCGN | NBY |
|---|---|---|
| Price | $1.56 | $8.68 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 4.1M | 2.6M |
| Earning Date | 11-05-2025 | 11-07-2025 |
| Dividend Yield | N/A | ★ 7.52% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | $5,370,000.00 | ★ $10,302,000.00 |
| Revenue This Year | $35.93 | $23.91 |
| Revenue Next Year | N/A | $32.05 |
| P/E Ratio | ★ N/A | $413.43 |
| Revenue Growth | 14.26 | ★ 390.34 |
| 52 Week Low | $0.52 | $0.46 |
| 52 Week High | $1.90 | $11.14 |
| Indicator | OCGN | NBY |
|---|---|---|
| Relative Strength Index (RSI) | 60.75 | 70.18 |
| Support Level | $1.32 | $4.31 |
| Resistance Level | $1.65 | $6.50 |
| Average True Range (ATR) | 0.11 | 1.58 |
| MACD | 0.02 | 0.42 |
| Stochastic Oscillator | 70.45 | 66.90 |
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.